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Abstract
Background: Tachycardia-induced remodeling likely plays an important role in atrial fibrillation (AF) maintenance and recurrence
21
after cardioversion, and Ca overload may be an important mediator. This study was designed to evaluate the relative efficacies of
21
selective T-type (mibefradil) and L-type (diltiazem) Ca -channel blockers in preventing tachycardia-induced atrial remodeling.
Methods: Dogs were given daily doses of mibefradil (100 mg), diltiazem (240 mg) or placebo in a blinded fashion, beginning 4 days
before and continuing through a 7-day period of atrial pacing at 400 bpm. An electrophysiological study was then performed to assess
changes in refractoriness, refractoriness heterogeneity and AF duration. Results: Mean duration of burst-pacing induced AF was similar in
placebo (5676203 s) and diltiazem-treated (9636280 s, P5NS) animals, but was much less in mibefradil-treated dogs (3.660.9 s,
P,0.002) and non-paced controls (6.662.7 s). In contrast to mibefradil, diltiazem did not alter tachycardia-induced refractoriness
abbreviation or heterogeneity. To exclude inadequate dosing as an explanation for diltiazem’s inefficacy, we studied an additional group
of dogs treated with 720 mg/day of diltiazem, and again noted no protective effect. Acute intravenous administration of diltiazem to
control dogs failed to alter atrial refractoriness or AF duration, excluding a masking of remodeling suppression by offsetting
21profibrillatory effects of the drug. Conclusions: Whereas the selective T-type Ca -channel blocker mibefradil protects against atrial
remodeling caused by 7-day atrial tachycardia, the selective L-type blocker diltiazem is without effect. These findings are potentially
important for understanding the mechanisms and prevention of clinically-relevant atrial-tachycardia-induced remodeling. Ó 2001
Elsevier Science B.V. All rights reserved.
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1. Introduction available therapy, there has been interest in developing
drug therapy directed against novel therapeutic targets,
Atrial fibrillation (AF) is an extremely common arrhyth- including the substrate for arrhythmia [4]. One potentially
mia, with an incidence that is increasing with the aging of interesting target is the remodeling process leading to
the population [1,2]. The treatment of AF remains subopti- AF-promoting electrophysiological changes that result
mal, with antiarrhythmic drugs to maintain sinus rhythm from atrial tachycardias, particularly AF [5]. Sustained
being plagued by a significant risk of ventricular pro- atrial tachycardia causes a variety of electrophysiological
arrhythmia [3]. Because of the limitations of presently alterations, including atrial effective refractory period
(ERP) abbreviation [6–10] and increases in refractoriness
heterogeneity [10,11], that promote AF inducibility and
maintenance.
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21There is evidence for Ca -overload as an initiating 2. Methods
signal for tachycardia-induced remodeling [5,9,12]. Ex-
21perimental and clinical studies suggest that Ca -channel 2.1. Instrumentation for rapid pacing
blockers may prevent the effects of atrial tachycardia on
atrial ERP [9,13–15] and mechanical properties [16,17]. Adult mongrel dogs (27.160.6 kg, n537) were anes-
The clearest evidence comes from studies of short-term thetized with pentobarbital (30 mg/kg i.v., additional
AF, the effects of which on atrial electrophysiology, doses of 4 mg/kg as needed). In an initial procedure, tined
arrhythmia promotion and mechanical dysfunction are unipolar pacing leads were inserted in the right atrial (RA)
prevented [13,14,16,17]. Studies of longer-term verapamil appendage (RAA) and in the right ventricular (RV) apex
administration have provided varying results [15,18]. under fluoroscopic guidance and connected to pacemakers
A retrospective analysis of clinical data showed that implanted subcutaneously in the neck. AV block was
21patients treated with either b-blockers or Ca antagonists, created with radiofrequency energy (30–40 W for 20–30
when considered as a single group, appeared to have s). The average number of radiofrequency applications was
reduced AF recurrence after cardioversion (differences 1.960.4. No dogs recovered AV-nodal conduction during
21
were not significant for either the b-blocker or Ca the study. The ventricular demand pacemaker was pro-
antagonist group alone) [19]. These findings have led to grammed to capture the ventricles at 80 bpm, and the atrial
speculation that I blockers may prevent tachycardia- pacemaker was activated to pace the atria with twice-Ca.L
induced remodeling and constitute useful adjunctive threshold pulses at 400 bpm. Atrial and ventricular pacing
therapy for AF patients. This suggestion contrasts with a were applied continuously during the 7-day rapid atrial
recent report of apparent inefficacy of verapamil in pre- pacing period (days 5–12, Fig. 1) prior to electrophysio-
venting remodeling caused by long-term atrial tachycardia logical study. Animal handling procedures were approved
[18]. by the Montreal Heart Institute Animal Ethics Committee
21In a previous study, we showed that the T-type Ca - and followed the guidelines of the Canadian Council for
current (I ) blocker mibefradil reduces electrophysio- Animal Care (CCAC).Ca.T
logical remodeling caused by 7 days of atrial tachycardia
in dogs [20]. Although most studies of mibefradil show it 2.2. Experimental protocol
21to be much more potent as a T-type Ca -channel blocker
than as an L-type blocker [21–23], the drug nevertheless In rapidly-paced dogs, one 100 mg tablet /day of mibef-
can clearly inhibit L-type channels considerably [24]. The radil (n512 dogs), one 240 mg tablet /day of Cardizem-
possibility cannot therefore be excluded that mibefradil’s CD, a slow-release diltiazem preparation (n510 dogs), or
I -blocking properties are responsible for its ability to matching placebo (n515 dogs) was given in a blindedCa.L
prevent atrial tachycardia-induced electrical remodeling. fashion, beginning 4 days before pacemaker implantation
The recently-reported inefficacy of verapamil [18] could and continuing until 24 h before the day of electro-
have been due to collateral properties, such as verapamil’s physiological study (Fig. 1). Although we have reported on
1
strong K -channel blocking action [25], to inadequate oral the effects of mibefradil in this model in a previous
doses (plasma concentrations were not measured) or to publication [20], we felt that it was essential to study the
contaminating effects of acute intravenous verapamil ad- drug in another series of dogs to compare directly and in a
ministration, which was given to all dogs in the chronic blinded fashion the effects of mibefradil with those of
verapamil group at the time of electrophysiological study diltiazem to minimize the possibility of erroneous conclu-
and could have had acute AF-promoting effects. In order to sions due to time-related and inter-animal variation or to
address the issue of the potential role of T- vs. L-type bias. Blood samples were obtained prior to anesthesia on
21Ca -channel blocking action in preventing atrial remodel- study days for subsequent measurement of plasma dil-
ing, we compared the effects of mibefradil with those of tiazem concentration by high-pressure liquid chromatog-
the highly-selective I -blocker diltiazem on atrial re- raphy. A group of size-matched dogs (n512) withoutCa.L
modeling caused by 7 days of rapid atrial pacing in the pacemaker implantation was used as a control group
dog. We chose to study diltiazem because, in contrast to (Table 1).
verapamil, which inhibits currents carried by the rapid The surface ECG was recorded every 2 days following
1delayed-rectifier K -clone HERG at similar concentrations pacemaker-implantation to confirm maintained atrial and
to those required to block I , diltiazem block of HERG ventricular pacing and AV-block. On the study day, dogsCa.L
requires concentrations 100-fold greater than those that were anesthetized with morphine (2 mg/kg s.c.) and a-
inhibit I [25]. A 7-day period of rapid pacing was chloralose (120 mg/kg i.v. load, 29.3 mg/kg/h). The atrialCa.L
chosen because I downregulation is quite significant pacemaker was then deactivated and a median sternotomyCa.L
after 7 days, with only small additional decreases noted performed. The study preparation and instrumentation
after 42 days of rapid pacing [26]. Preliminary results of were as previously described [10,11]. A mapping system
the present study have been presented in abstract form was connected to five arrays covering the atrial epicardial
[27]. surfaces with 240 bipolar electrodes as in our previous
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Fig. 1. Schematic outline of study design. PM5pacemaker. Mibefradil, placebo or diltiazem were received in coded bottles and administered as a single
morning dose, beginning 4 days before the onset of rapid-pacing and continuing during the 7-day rapid-pacing period. The last dose was administered 24 h
before electrophysiological study.
work [20]. Signals were filtered (10–900 Hz), digitized inferior free wall. ERP was determined in the same regions
(12-bit resolution, 2-kHz sampling), and transmitted into a as for CV measurements, allowing for the calculation of
Silicon Graphics computer. Activation data were analyzed local wavelength as the product of mean local CV and
off-line with computer-determined peak-amplitude criteria, ERP. A 15-stimulus basic train at a basic cycle length
and data for each electrode were reviewed manually. (BCL, 2-ms, twice-threshold current pulses) of 300 ms was
followed by a premature extrastimulus (2-ms, twice-thres-
2.3. Electrophysiological study hold current) at a progressively-increasing coupling inter-
val and a 2-s pause to observe the response between trains.
Atrial effective refractory period (ERP) and conduction The coupling interval was increased by 10-ms increments
velocity (CV) were measured during stimulation at sites in to obtain an initial ERP estimate. The measurement was
various atrial regions as in previous work [11]. Activation then repeated with 5-ms increments and the resulting value
maps for CV measurement were obtained after 60 s at a taken as the ERP if it was within 10 ms of the first
basic cycle length (BCL) of 300 ms. CV was measured estimate. In the case of a $10-ms difference between
with the use of two parallel sets of electrodes (four bipolar measurements, a third measurement with 5-ms steps was
electrodes / set) during local pacing in each of five regions: obtained and the mean of all three ERP values was used.
Bachmann’s bundle (BB), the left atrial (LA) appendage AF vulnerability was determined from the response to
(LAA), the RAA, the RA superior free wall and the RA single S extrastimuli (S s) at coupling intervals of 5 and2 2
Table 1
aOverall group variables
†Control Placebo Mibefradil Diltiazem P value
(n512) (n515) (n512) (n510)
Weight (kg) 27.460.9 26.760.3 27.360.3 27.260.4 NS
Sinus CL (ms) 396628 410613 636634* 449632 ,0.001
Mean BP (mmHg) 8364 8064 7063 7463 NS
Number of sites for ERP 16.060.3 13.061.3 15.560.4 11.561.9 NS
Atrial diastolic threshold (mA) 0.6860.05 0.6260.03 0.6260.04 0.6060.03 NS
a CL, cycle length; BP, blood pressure; ERP, effective refractory period.Values are mean6S.E.M. * P,0.002 vs. placebo, diltiazem and control by range
†test. P value for column effects (control vs. placebo vs. mibefradil vs. diltiazem) by ANOVA.
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10 ms longer than the ERP at each site used for ERP Wallis rank sum test (when data could not be assumed to
determination. The vulnerability at each site was defined be normally-distributed) was used for multiple-group
by the ability of single S s to induce in a reproducible comparisons, followed by a range test. A chi-square test2
fashion AF that lasted .1 s. Overall vulnerability in each was used for contingency comparisons. Averages are given
dog was defined as the percentage of sites at which AF as mean6S.E.M., and a two-tailed P,0.05 was considered
was inducible. Because in some dogs AF was not inducible statistically-significant.
by single extrastimuli, AF was also induced by stimulating
the RAA with 10-Hz, 2-ms stimuli at four times threshold
current for 2–10 s. To calculate mean AF duration, AF 3. Results
was induced with burst pacing ten times for AF duration
,10 min and twice for AF duration .10 min. AF that 3.1. Overall electrophysiological changes
lasted .20 min was terminated by direct current electrical
cardioversion, and 20 min allowed before repeating AF Control, placebo, mibefradil and diltiazem dogs showed
induction. no significant differences in size, number of sites for ERP
determination, and atrial diastolic threshold (Table 1).
2.4. Data analysis Mibefradil-treated dogs had a slower sinus rate compared
to placebo, control and diltiazem dogs, consistent with the
21The CV was determined in each region as previously role of T-type Ca channels in sinus-node automaticity
described [11] and the overall CV for each dog calculated [21].
from the average of the five regional CV values. Overall
wavelength was calculated as the mean of all ERP values 3.2. Effects on AF vulnerability and maintenance
in each dog times the mean CV (not significantly different
from the value obtained by multiplying ERP in each region Placebo-treated dogs subjected to 7-day rapid atrial
by local CV and averaging the values). The coefficient of pacing had significantly-increased AF duration (Fig. 2A)
ERP variance, calculated as (S.D. /mean)3100%, was used and vulnerability to AF induction (Fig. 2B). AF duration
as an index of ERP heterogeneity. The number of sites for of mibefradil-treated dogs (6.662.7 s) was reduced com-
ERP determination in each region was equivalent across pared to placebo-treated dogs (5676203 s, P,0.002) and
dogs and between groups. similar to non-paced control dogs (3.660.9 s, P5NS). In
Statistical comparisons between two groups only were contrast, the AF duration of diltiazem-treated rapidly-
performed by Student’s t-test or the Mann–Whitney rank paced dogs (9636280 s) was not significantly different
sum test (for non-normally distributed data). Analysis of from placebo-treated rapidly-paced dogs and substantially
variance (ANOVA, for parametric data) or a Kruskal– greater than non-paced controls (P,0.002). Changes in
Fig. 2. Changes in AF duration (A) and AF vulnerability (B) induced by 7 days of rapid atrial pacing in placebo (PLA), mibefradil (MIB) and diltiazem
11(DTZ) dogs. ** P,0.002 vs. CTL, P,0.002 vs. PLA and DTZ.
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vulnerability to AF induction by single atrial premature average value in non-paced control dogs (11463 ms). In
complexes were qualitatively similar to those in AF diltiazem-treated rapidly-paced dogs, ERP averaged 7464
duration. In placebo-treated dogs, rapid pacing led to a ms, similar to placebo-treated animals (7963 ms), with
highly-significant increase in vulnerability, with AF in- both significantly reduced from control non-paced dogs
duced by single extrastimuli at over 40% of sites per dog, (Fig. 3A). Wavelength changes (Fig. 3C) reflected ERP
compared to about 2% in non-paced controls (P,0.002, alterations, with mibefradil showing significant protection
Fig. 2B). Mibefradil greatly decreased vulnerability (AF against tachycardia-induced abbreviation and diltiazem no
induced at fewer than 10% of sites, P,0.002 vs. placebo). effect. In contrast to placebo-treated rapid-pacing dogs,
Diltiazem administration was no better than placebo in mibefradil-treated dogs had a coefficient of variation in
reducing AF vulnerability in rapidly-paced dogs, with AF ERP (17.061.2%) which was not significantly different
inducible at nearly 60% of sites (P5NS vs. placebo, from the value in control dogs (14.160.8%). Diltiazem-
P,0.002 vs. mibefradil). treated rapidly-paced dogs had similar ERP heterogeneity
(28.362.0%) to placebo animals (26.761.9%), with both
3.3. Changes in electrophysiological properties values significantly greater than in control (non-paced) and
mibefradil-treated rapidly-paced dogs.
Placebo-treated dogs subjected to 7 days of rapid-pacing
had significantly reduced ERP (Fig. 3A) and unchanged 3.4. Regional changes in electrophysiological properties
CV (Fig. 3B). Wavelength changes paralleled those in ERP
(Fig. 3C). In addition to decreasing the absolute ERP Regional ERP differences under control conditions in
value, rapid pacing also increased ERP heterogeneity (Fig. dogs are related to discrete ionic current distributions [28],
3D). Mibefradil prevented the ERP-abbreviating effect of and increased ERP heterogeneity is important in tach-
rapid pacing, with the mean ERP in mibefradil-treated ycardia-induced remodeling [11]. Fig. 4 shows an analysis
dogs (10365 ms) not significantly different from the of changes produced by each intervention in ERP values
Fig. 3. Changes in ERP (A), conduction velocity (B), wavelength (ERP3CV) (C) and ERP heterogeneity (D) at a BCL of 300 ms induced by 7 days of
11
rapid atrial pacing in placebo (PLA), mibefradil (MIB) and diltiazem (DTZ) groups. ** P,0.002 vs. CTL, P,0.002 vs. PLA and DTZ.
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Fig. 4. Changes in intraregional atrial ERP induced by rapid atrial pacing in placebo (PLA), mibefradil (MIB) and diltiazem (DTZ) dogs. * P,0.02,
1 11
** P,0.002 vs. CTL, P,0.02, P,0.002 vs. PLA and DTZ.
for each of four regions for which sufficient data were ERP (P5NS for each), consistent with diltiazem’s lack of
available. The results indicate that for each region studied, effect on mean ERP and AF duration.
rapid pacing significantly decreased ERP values in placebo The lowest diltiazem concentration 24 h after the last
and diltiazem-treated dogs, but had much less (and statisti- dose of diltiazem averaged 2867 ng/ml, just below the
cally non-significant) effect in mibefradil-treated animals. therapeutic concentration of 40 ng/ml [29]. We therefore
considered the possibility that diltiazem’s inefficacy was
due to insufficient plasma concentrations and studied an
3.5. Diltiazem plasma concentrations and effects of additional group of four dogs treated with 3-fold larger
high-dose diltiazem doses, 720 mg/day (on a per-weight basis, equivalent to
about 1680 mg/day, or five times the maximum clinical
In our previous study, we showed that plasma mibefradil dose, in man). The same protocol as shown in Fig. 1 was
concentrations were significantly related to AF duration used, except that the dose of diltiazem consisted of four
and ERP in individual rapidly-paced dogs, consistent with 180-mg tablets each morning. This dose significantly
concentration-dependent protection [20]. The effective reduced arterial pressure, from 12268/6665 mmHg in
trough mibefradil concentrations in that study were in the placebo dogs to 9964/4463 mmHg in diltiazem-treated
range of 100–400 ng/ml (0.2–0.7 mM). We were unable to dogs (P50.01). The sinus cycle length was also sig-
obtain mibefradil plasma concentration measurements for nificantly prolonged by high-dose diltiazem, from 396628
the dogs in the present study. However, we did measure to 605638 ms (P,0.05), indicating significant pharmaco-
plasma diltiazem concentrations and evaluated the relation- logical effects. After 7 days of rapid pacing, ERP in these
ship with AF duration or atrial ERP. The correlation dogs (BCL 300 ms) was 81610 ms, not significantly
coefficients were 20.42 (for AF duration) and 20.12 for different from placebo-treated dogs subjected to atrial
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tachycardia. Similarly, AF duration averaged 13426428 s the present study, we compared directly the effects of
(vs. 5676203 s for placebo-treated rapidly-paced dogs), mibefradil with those of the I blocker diltiazem, findingCa.L
AF was inducible at 63624% of sites (compared to that the latter does not share mibefradil’s protective
4368% for placebo), and the coefficient of ERP hetero- actions. The discrepancy between our finding of inefficacy
geneity averaged 2463% (vs. 2762% for placebo), none of I blockade in 7-day atrial tachycardia-inducedCa.L
significantly different from atrial-tachycardia dogs treated remodeling and previous studies of I blockers inCa.L
with placebo or low-dose diltiazem. Thus, high-dose tachycardia-induced remodeling may be due to the dura-
diltiazem had no greater anti-remodeling effect than low- tion of atrial tachycardia. Most previous studies involved
dose and the lack of diltiazem effect cannot be attributed to atrial tachycardia of ,24-h duration. The mechanisms of
inadequate dosing. short-term atrial-tachycardia remodeling are likely to be
quite different from those of longer-term remodeling, the
3.6. Effects of acute diltiazem administration former being primarily functional and the latter related to
altered gene-expression [5]. Thus, the role of I mayCa.L
21The acute administration of Ca antagonists has been well be different in mediating the effects of shorter-term
reported to promote AF maintenance [30]. We considered vs. longer-term tachycardia. In agreement with this idea,
the possibility that the lack of benefit from diltiazem may the effects of verapamil on AF promotion caused by atrial
have been due to an acute pro-fibrillatory effect of the tachycardia lasting 24 h or greater [15,18] are very
drug, i.e. that remodeling might have been prevented, but different from its clear efficacy against AF promotion after
that residual drug present in the blood may have itself 10–20 min of AF [12,13].
decreased ERP and promoted AF, offsetting the effects
mediated by inhibition of remodeling. To evaluate this
4.2. Novel findings and potential significancepossibility, we infused diltiazem intravenously to four
additional non-paced dogs at loading and maintenance
This is the first study of which we are aware to comparedoses previously shown to produce stable plasma diltiazem
simultaneously the effects of a selective I blocker and aconcentrations [31]. Acute administration of diltiazem did Ca.L
selective I blocker on tachycardia-induced remodelingnot significantly alter atrial ERP, which averaged 11262 Ca.T
in a controlled fashion. The results clearly showed noms (BCL 300 ms) before and 11663 ms after the drug, nor
benefit from the selective I blocker diltiazem, inAF duration, which averaged 8.466.0 and 25.8614.6 s, Ca.L
contrast to the clear efficacy of the I blocker mibef-respectively. Ca.T
radil. I down-regulation appears to play a central roleCa.L
in long-term atrial tachycardia-induced action potential
duration and refractory period changes [26]. Tachycardia-4. Discussion
related ionic alterations are caused by decreased con-
21 centrations of mRNA encoding ion channel a-subunitsWe have shown that the Ca -channel blockers dil-
[32]. The nature of the signal transduction system leadingtiazem and mibefradil, with different selectivities for T- vs.
to ion-channel mRNA changes is unknown, but ourL-type channels, have markedly different effects on elec-
findings point to a potentially-important role of I . Thetrophysiological remodeling caused by 7-day atrial tachy- Ca.T
21
absolute magnitude of Ca entry via I seems to becardia. Whereas the T-type blocker mibefradil strongly Ca.T
substantially less than that via I for normal atrialinhibits the ERP-altering and AF-promoting effects of Ca.L
myocytes [26]. On the other hand, I decreases withatrial tachycardia, the L-type blocker diltiazem has no Ca.L
tachycardia, as a result of both functional accumulation ofsignificant effects.
inactivation [33] and ion-channel down-regulation
21 [32,34,35]. It is therefore possible that at sustained rapid4.1. Relationship to previous studies of Ca channel
21
rates I plays a relatively more important role in Cablockers in tachycardia-induced remodeling Ca.T
entry. The negative findings with diltiazem indicate that
21 I inhibition alone is insufficient to prevent tachycardia-L-type Ca channel blockade has been shown to inhibit Ca.L
induced remodeling; however, they do not exclude theatrial remodeling caused by short-term (10–20 min) atrial
possibility that inhibition of both I and I is needed,tachycardia [13,14,16,17]. ERP changes induced by 7–24 Ca.L Ca.T
21h of atrial tachycardia are attenuated by verapamil since mibefradil can affect both Ca -currents [21–24]. It
21[8,15,18]. Verapamil appears to have no effect on ERP or may be that the prevention of Ca overload during long-
AF vulnerability changes induced by longer-term atrial term tachycardia (.24 h) requires the inhibition of both
21tachycardia [18], although in the latter study plasma drug Ca entry pathways. Alternatively, I may haveCa.T
concentrations were not measured to ensure that adequate privileged access to systems regulating DNA transcription.
blood levels were achieved by oral dosing. We previously Clinically, the notion of preventing atrial tachycardia-
showed that mibefradil attenuates tachycardia-induced induced remodeling is an attractive new approach to
ERP, AF duration and AF vulnerability changes [20]. In improving the management of AF [5,19]. Tielemans et al.
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[19] analyzed retrospectively the rate of reversion to AF that I inhibition is the mechanism of protection. OtherCa.T
1following cardioversion. They found that patients taking possibilities, including K -channel [41] and cytochrome
21Ca -channel blockers (including verapamil, ditiazem and [42] inhibition, as well as presently unrecognized actions
dihydropyridines, breakdown not specified) had a greater of the drug, could also have played a role.
tendency to remain in sinus rhythm (P50.06). Significant We used radiofrequency ablation to prevent variations in
(P50.03) improvements in sinus rhythm maintenance were ventricular response rate (due to drug effects on the AV
noted when patients on b-blockers were grouped together node) from contaminating the results. Control of the
21
with patients on Ca -antagonists and considered to ventricular rate was essential, because otherwise there may
21
constitute an ‘intracellular Ca -lowering drug’ group. Our have been a more rapid ventricular rate in control than
findings, particularly in combination with the similar drug (especially diltiazem) treated dogs. This could have
observations on verapamil of Lee et al. [18], raise ques- resulted in drug effects on atrial remodeling due to
tions about the ability of I blockers to prevent atrial differences in ventricular function rather than atrial re-Ca.L
tachycardia-induced electrophysiological remodeling. A modeling per se. The potential disadvantages of this
recent study [36] showed early recurrence (within 24 h) approach include atrial consequences of loss of AV
following electrical cardioversion of AF in two of 44 synchrony and possible (albeit unlikely) direct effects of
diltiazem-treated patients compared to three of 30 patients AV nodal ablation on the atria. Since any such collateral
on digoxin (P5NS). Recurrence rates at 1 month were also effects would have applied equally to placebo, mibefradil
similar in diltiazem (56%) and digoxin (78%) treated and diltiazem groups, we don’t believe they affected our
patients. The present findings confirm our previous work results.
[20], showing that it is possible to prevent pharmacologi-
cally the electrophysiological consequences of atrial tach-
ycardia-related remodeling. Mibefradil has been removed Acknowledgements
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